Health insurers rise after US lifts 2027 Medicare Advantage payment rates

CMS will raise 2027 Medicare Advantage payment rates by 2.48% on average, plus a ~2.5% boost from risk-adjustment changes for a total increase of about 5%, adding more than $13 billion to MA plan payments. The raise is well above the January proposal of 0.09% and RBC's 1%-1.5% expectation, prompting insurer stock rallies (Humana +10.7%, UnitedHealth +6.9%; CVS, Elevance, Centene, Molina +3.6%-6%). This materially improves insurers' pricing, benefit and margin outlook for 2027 bids and is sector-positive for MA-focused insurers.

Analysis

Scale and underwriting sophistication are the primary durable winners here: firms that already run large Medicare Advantage books and have integrated data/PBM assets will convert incremental payment tailwinds into higher margin retention and reinvestment in network and benefits, while smaller or narrow-network competitors will struggle to match benefit generosity without raising bids. The change boosts the value of accurate HCC capture and analytics — expect outsized earnings leverage at insurers with stronger chart-review and encounter-data programs, and flow-through to EBITDA of several hundred basis points over a 12–24 month window as bids are re-priced and reserves de-risk.

Second-order effects cut across provider negotiation dynamics and capital allocation: payors with improved rate levers will accelerate value-based contracting and narrow-network design to defend margin gains, pressuring some hospitals and post-acute providers on price and volumes. At the corporate level, excess free cash flow is likely to be redeployed into M&A and share buybacks rather than material premium reductions, which should compound returns for incumbent scale players and raise the bar for regional entrants.

Key risks are political/audit reversal and utilization volatility. A retroactive CMS correction, heightened audits of risk scores, or an enrollment mix shift toward higher-cost cohorts could materially compress implied upside — these are event risks with concentrated windows (rulemaking, bid submissions, and mid-year audit cycles) over the next 3–18 months. Market reactions are likely front-loaded; the sensible horizon to judge fundamental re-rating is earnings cycles over the next 2 quarters to 2 years.

From a positioning standpoint the headline move is necessary but not sufficient: some of the intraday repricing reflects headline arbitrage and will unwind, while persistent structural gains favour concentrated, duration-aware exposure to the highest-quality MA franchises. Volatility will be elevated around the next round of regulatory publications and earnings, creating both tactical shorts in overpriced options and strategic long opportunities in equity or call spreads.

Key Decisions for Investors

• Long HUM (6–12 month horizon): buy a 3–6 month call spread roughly 5–10% OTM (debit structure) or accumulate stock size up to 2–3% portfolio weight with a 7–8% tactical stop; target 20–35% upside if risk-adjustment tailwinds sustain and auditors/legislators do not reverse. Rationale: highest operational leverage to MA underwriting and risk-score improvements.
• Long UNH (3–9 month horizon): purchase 6–9 month 5–10% OTM call spreads or buy stock with a 5% trailing stop; expect steadier, lower-volatility capture of margin expansion and optionality into PBM/provider deals. Size 2–4% portfolio; asymmetric R/R if bids and M&A optionality compound.
• Pair trade (3–12 months): long ELV + UNH vs short CNC (equal notional) — size modest (net market-neutral 1–2% each leg). Thesis: scale MA franchises re-rate higher while Medicaid/less MA-focused peers show smaller flow-through; expected spread compression of 5–12% favoring the long leg absent regulatory reversals.
• Tactical options/volatility trade (0–3 months): sell short-dated calls or implement covered-call overlays on names that spiked intraday (enter within 1–3 trading days) to harvest premium; alternatively buy cheap protective puts if holding stock into next CMS/earnings event. Keep notional small (1% portfolio) due to gamma risk around headlines.